Targeted delivery of bioaffecting compounds for the treatment of cancer
AssigneeFaulk Pharmaceuticals, Inc.
InventorW. Page Faulk
Life of this patent
Estimating the term…
Abstract
A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anti-cancer drug and a targeting protein, wherein said anti-cancer drug is selected from the group consisting of heat sensitizers, photosensitizers and apoptosis inducing compounds, a method for making such a conjugate, and methods for using the conjugate. The targeting protein is preferably transferrin.
Claims3
A homogeneous conjugate comprising a targeting agent linked to a bioaffecting material via a glutaraldehyde linker, wherein said bioaffecting material is doxorubicin and said targeting agent is transferrin, wherein said homogeneous conjugate is free of dimers, trimers and aggregates and wherein said conjugate has a doxorubicin:
- transferrin molar ratio of about 2:1.
Dependencies are inferred from the claim text.